Targeted radiotherapy biotech out of Longitude Capital raises a fresh $75M
Alpha-9 Theranostics, a targeted radiotherapy biotech launched out of Longitude Capital last year, has raised $75 million in a Series B round.
Interestingly, however, the Vancouver- and Boston-based biotech doesn’t have one lead candidate. Rather, it has five that it plans to take into early human testing before moving forward with formal trials.
“We’re taking them all into the clinic,” Alpha-9 CEO and Longitude Capital venture partner David Hirsch told Endpoints News. “And then based on the imaging and dosimetry data, we’ll pick from that which we advance into clinical trials, which is really where costs start to accelerate.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.